share_log

18 Analysts Have This To Say About Crinetics Pharmaceuticals

Benzinga ·  May 14 12:00

In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings711000
Last 30D01000
1M Ago12000
2M Ago33000
3M Ago35000

The 12-month price targets, analyzed by analysts, offer insights with an average target of $62.78, a high estimate of $97.00, and a low estimate of $48.00. This upward trend is apparent, with the current average reflecting a 24.89% increase from the previous average price target of $50.27.

price target chart

Breaking...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment